Earnings Summary

BridgeBio Pharma Inc’s revenue fell -99.86% since last year same period to $0.07Mn in the Q2 2022. On a quarterly growth basis, BridgeBio Pharma Inc has generated -95.65% fall in its revenue since last 3-months.

BridgeBio Pharma Inc’s net profit jumped 99.99% since last year same period to $-0.01Mn in the Q2 2022. On a quarterly growth basis, BridgeBio Pharma Inc has generated 99.99% jump in its net profits since last 3-months.

BridgeBio Pharma Inc’s net profit margin jumped 92.51% since last year same period to -13.36% in the Q2 2022. On a quarterly growth basis, BridgeBio Pharma Inc has generated 99.88% jump in its net profit margins since last 3-months.

BridgeBio Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.63 - a 43.24% jump from last quarter’s estimates.

BridgeBio Pharma Inc’s earning per share (EPS) estimates for the current year stand at -0.63.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. BridgeBio Pharma Inc’s return on assets (ROA) stands at -0.35.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. BridgeBio Pharma Inc’s return on equity (ROE) stands at -17.9.

BridgeBio Pharma Inc declared 0 dividend per share during the earnings announcement for Q2 2022.